AstraZeneca announced today that anifrolumab (Saphnelo or anifrolumab-fnia) was approved by the FDA for that treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy. https://t.co/22HVA32IAh https://t.co/xZNfepcDLQ